Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10055017 | 0.92 | CLK4 (0.52) | HTTCLK4MAPK13RAF1MAPK9 | |
| Sulfuric Acid SCHEMBL28646821 | 0.92 | HTT (0.53) | HTTSMN1; SMN2CYP1A2CYP2C19TSHR | |
| SCHEMBL18434511 | 0.84 | HTT (0.55) | HTTSMN1; SMN2CYP1A2CYP2C19TSHR | |
| SCHEMBL10055031 | 0.84 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2CLK4USP2MAPK13 | |
| SCHEMBL14272989 | 0.84 | HDAC1 (0.51) | HTTCYP1A2CYP2C19TSHRCYP2D6 | |
| SCHEMBL15952526 | 0.81 | HTT (0.82) | HTTSMN1; SMN2CYP1A2CYP2C19TSHR | |
| SCHEMBL28860465 | 0.80 | MKNK1 (0.42) | HTTCYP1A2CYP2C19CLK4MAPT | |
| SCHEMBL12597156 | 0.78 | NPSR1 (0.55) | HTTSMN1; SMN2CYP1A2CYP2C19TSHR | |
| SCHEMBL22191109 | 0.78 | LCK (0.50) | MEN1KMT2AALDH1A1HPGDLCK | |
| SCHEMBL21797166 | 0.77 | CDC7 (0.46) | HTTCYP1A2CYP2C19TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111554892-B | Lithium battery negative electrode material Co3O4Preparation method of nano-fiber | 宁波大学 | 2021-07-30 | — | — | CN | claimed |
| CN-111554892-A | Lithium battery negative electrode material Co3O4Preparation method of nano-fiber | 宁波大学 | 2020-08-18 | — | — | CN | claimed |
| CN-111564619-B | Preparation method of carbon-coated nano nickel lithium battery material | 宁波大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-114286668-A | Local, sustained, controlled release implantable depot of therapeutic agents for treating cancer and related symptoms and conditions | 铸造疗法股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-111554892-B | Lithium battery negative electrode material Co3O4Preparation method of nano-fiber | 宁波大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-109153700-B | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV保健英国第五有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-111867608-A | Phage therapy for acne and biofilm | 拜欧麦克斯有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-111554892-A | Lithium battery negative electrode material Co3O4Preparation method of nano-fiber | 宁波大学 | 2020-08-18 | — | — | CN | disclosed |
| CN-104725397-A | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB | 2015-06-24 | — | — | CN | disclosed |
| CN-101972226-B | Veterinary doxycycline hydrochloride injection and preparation method thereof | ZHENGZHOU HOUYI PHARMACEUTICAL | 2012-11-07 | — | — | CN | disclosed |
| CN-101972226-A | Veterinary doxycycline hydrochloride injection and preparation method thereof | ZHENGZHOU HOUYI ENTPR GROUP CO LTD | 2011-02-16 | — | — | CN | disclosed |
| US-7279475-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1549621-A1 | FLUORINATED PHENYL-NAPHTHALENYL-UREA COMPOUNDS AS INHIBITORS OF CYTOKINES INVOLVED IN INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-6872726-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004014870-A1 | FLUORINATED PHENYL-NAPHTHALENYL-UREA COMPOUNDS AS INHIBITORS OF CYTOKINES INVOLVED IN INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | IL1B, IL1A, TNF | HTT 4500/4885SMN1; SMN2 4000/4885CYP1A2 558/4885 |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | IL1B, MPO, IL1A | HTT 3495/4885SMN1; SMN2 4452/4885CYP1A2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.